Best clinical trials AI

Nearly every published answer to this question is an ordered list, and an ordered list requires a weighting: a decision about which failure matters most. That decision belongs to the sponsor or site carrying the study, not to whoever wrote the list. Publishing an order does not remove the weighting, it hides it inside a position number that looks like a measurement.

Two sponsors can correctly reach opposite conclusions about the same vendor. One running a large phase three cardiovascular study across community sites needs breadth of data access above everything. One running a rare disease study where the eligible population is measured in hundreds needs matching precision and will accept a narrow integration to get it. There is no order that is right for both.

So what follows is the whole roster graded on the same axes, then shortlists cut by failure mode. It is a longer read than a top ten and it is the only version of this page that would survive being checked.

Of the 46 vendors graded here, 19 are primarily clinical trials companies. The remaining 27 reach trials through something else they were already doing: sequencing, digital pathology, imaging analysis, real world evidence, remote monitoring. They appear on this page because a sponsor evaluating them is evaluating a trials capability, whatever the company calls itself.

That matters practically, in two directions. A buyer who searches only for clinical trial software will not see most of the field, and will end up comparing a shortlist that is missing the companies with the deepest data. A buyer who does see the whole field has to be careful not to compare a full trial operations platform against a molecular profiling company on the same axes and conclude that one is worse.

The grades do not resolve that for you and are not meant to. They tell you what each company has published against the same fifteen questions, which is the input to that judgement rather than a substitute for it.

Every vendor in the index carries a grade on all 15 axes before it is published at all, so this table compares the same questions answered for every vendor rather than the results of uneven research. Counts are of vendors, as of August 31, 2026.

Read the top of that table and the category looks like what it is: an industry that grew up inside clinical research and publishes accordingly. 15 vendors hold a top grade on Clinical and Operational Evidence, 13 on Autonomy and Oversight Model, 8 on EHR and Interoperability Depth, and 12 on FDA and Regulatory Status, which here mostly records a clearly stated regulatory position rather than a clearance. 7 axes have nobody at the bottom grade at all.

Then read the middle, which is where the surprise is. HIPAA and BAA Posture returns 2 top grades and AI Safety and PHI Stewardship returns 3. Security Certifications and Trust Center returns 3, with 3 at the bottom. A category that publishes its outcomes carefully has not, on the whole, published the terms on which it handles the data those outcomes came from.

And Commercial Transparency is the thinnest commercial axis on the page: 2 top grades against 8 at the bottom. Sponsor procurement runs on scoped quotes, so this is expected, but expected is not the same as harmless when you are trying to size a pilot.

This is the finding this page was worth building for. 2 of 46 vendors hold a top grade on HIPAA and BAA Posture. 3 hold a top grade on AI Safety and PHI Stewardship. The number holding a top grade on both is 0.

Those two axes are not redundant. The first asks whether the contractual position is published and readable: does the vendor sign a business associate agreement, on what terms, and can a counterparty see them before a call. The second asks what actually happens to the data: where it goes, what it trains, what is retained, what is de identified and how. A vendor can be strong on either while being silent on the other, and in this category most are.

The reason this matters more here than in a documentation product is the direction of the workflow. Ambient documentation processes an encounter that has already happened with a patient who is already a patient. Trial recruitment runs the other way: it reaches into records to find people who have not consented to anything, have no relationship with the sponsor, and in many cases will never be contacted at all. The screening happens whether or not the match succeeds.

The practical consequence is that this cannot be resolved by reading a website. Neither half of the pair is reliably public across this roster, so both belong in the first substantive conversation, before a data use agreement is drafted rather than during. Ask which entity holds the PHI at each step, whether the matching model is trained on your data or only run against it, and what the retention position is when the study closes.

1 of the 46 vendors here holds a top grade on AI Governance and Bias Disclosure, and 5 sit at the bottom grade. This is a thinner result than in most categories, and it lands on the one function where a systematic miss is invisible by construction.

A matching model that never surfaces a group does not produce an error anyone sees. It produces a slightly smaller candidate list, drawn from the patients whose records are complete, whose conditions are coded the way the model expects, and whose care happened inside the systems the vendor can read. Enrollment then looks efficient and the cohort quietly narrows.

Trial representativeness has moved from an ethical expectation to a documented regulatory one, and sponsors are increasingly asked to describe how they planned for it. A recruitment vendor that cannot describe how its model performs across populations is not a neutral tool in that conversation, it is an unexamined input to it.

The question to ask is narrow and answerable. Ask what the candidate pool looked like against the underlying population of the sites in question, ask what the vendor did the last time those two diverged, and treat a matching rate quoted without a denominator as no answer at all.

AI Liability and Recourse is the only axis on this page that returns a top grade for nobody at all, and 14 of 46 vendors sit at the bottom grade. Before reading that as a trials problem, note the scale of it: across all 554 vendors this index grades, in every category, exactly 1 earns an A on that axis.

It is an industry position rather than a category one. Published terms in health AI generally offer the service as is, disclaim warranties, and leave the buyer holding the output. In trials the buyer holding the output is the sponsor, whose regulatory accountability for the study was never transferable in the first place.

So the useful planning assumption is the plain one. The vendor is a supplier to a process you remain answerable for, and the review step that catches a bad match has to exist on your side of the line. Design that step first and choose the product that fits it.

Each list below is every vendor in the category holding the top grade on the named axes. They are not ranked, they are alphabetical, and a vendor appearing on none of them is not disqualified. It has not published what these axes ask for, which is a question to raise rather than a verdict.

An empty list is a result rather than a gap in the research. It says the question currently has no vendor level answer available in public, which makes it a demo question instead of a filter.

If more than one of these is your failure mode, take the intersection yourself rather than looking for a vendor that appears everywhere. Almost none do, which is the point of the next section.

The widest record in the category holds a top grade on 7 axes of 15. The median record holds 3. There is no vendor here that clears every bar, and a comparison built on the assumption that one exists will end in a tie broken by brand recognition.

This is also where the mixed nature of the roster shows up hardest. A vendor with deep evidence and thin contractual disclosure and a vendor with a strong trust center and no published outcomes are not competing on the same ground, and forcing them into one order destroys the only information that would have helped.

The right number of finalists is small and specific. Two or three vendors that clear your one non negotiable axis will produce a better process than ten that all look plausible on a capability grid.

Every clinical trials AI vendor in the index, each graded on all 15 axes with a source and a date on every judgement. Inclusion is not purchasable and no vendor pays for placement or review.